Track topics on Twitter Track topics that are important to you
Amid Celltrion's string of biosimilar approvals and launches in the US and Europe, its marketing and distribution arm Celltrion Healthcare...
* Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug
South Korean biopharmaceutical firm Celltrion has showcased data supporting the efficacy and safety of…
The European Medicines Agency has approved Celltrion's Truxima, a biosimilar for Roche Holding's leukemia treatment Rituxan/M -More-
South Korean biotechnology company Celltrion has announced advances in its biosimilar rituximab and trastuzumab programmes in China and Japan.
The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.
In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a...
Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s canc...